{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:06:51Z","timestamp":1790701611152,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T00:00:00Z","timestamp":1491523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["P50 MH 68036"],"award-info":[{"award-number":["P50 MH 68036"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["U01\u2010NS038455"],"award-info":[{"award-number":["U01\u2010NS038455"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004342","name":"Wyeth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009670","name":"National Alliance for Research on Schizophrenia and Depression","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Children of women treated with antiepileptic drugs (<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s) are at increased risk of adverse outcomes detectable in the neonatal period, which may be associated with the amount of <jats:styled-content style=\"fixed-case\">AEDs<\/jats:styled-content> in the fetal circulation. Placental passage of <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s can be measured by calculating the ratio of umbilical cord to maternal <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content> concentrations collected at delivery. The aims of this study were to determine the umbilical cord concentrations and umbilical\u2010to\u2010maternal ratios for <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s, and whether higher cord concentrations are associated with increased risk of neonatal complications. <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content> cord and maternal blood concentrations from 70 mother\u2013newborn dyads and neonatal complications were recorded. Logistic regressions were performed to determine the association between <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content> concentrations and complications. Mean umbilical\u2010to\u2010maternal ratios for total concentrations ranged from 0.79 for carbamazepine to 1.20 for valproic acid, and mean umbilical\u2010to\u2010maternal ratios for free concentrations ranged from 0.86 for valproic acid to 1.42 for carbamazepine, indicating complete placental passage. Neither umbilical cord concentrations nor umbilical\u2010to\u2010maternal ratios were associated with adverse neonatal outcomes. Additional investigations are warranted to delineate the relationship between quantified fetal <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content> exposure and neonatal complications.<\/jats:p>","DOI":"10.1111\/epi.13733","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T13:09:42Z","timestamp":1491570582000},"source":"Crossref","is-referenced-by-count":29,"title":["Placental passage of antiepileptic drugs at delivery and neonatal outcomes"],"prefix":"10.1111","volume":"58","author":[{"given":"Anna M.","family":"Bank","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital Boston Massachusetts U.S.A."},{"name":"Massachusetts General Hospital Boston Massachusetts U.S.A."},{"name":"Harvard Medical School Boston Massachusetts U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary N.","family":"Stowe","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences Little Rock Arkansas U.S.A."},{"name":"Arkansas Children's Hospital Research Institute Little Rock Arkansas U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Jeffrey","family":"Newport","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine Miami Florida U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine Atlanta Georgia U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Page B.","family":"Pennell","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital Boston Massachusetts U.S.A."},{"name":"Harvard Medical School Boston Massachusetts U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0464-0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.1017"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70107-7"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528030-00005"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602530701690390"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511730221"},{"key":"e_1_2_8_8_1","unstructured":"National Center for Biotechnology Information.PubChem compound database; CID 2554 3878 34312 1775 3121. Available at:https:\/\/pubchem.ncbi.nlm.nih.gov. Accessed January 27 2017."},{"key":"e_1_2_8_9_1","unstructured":"Center for Drug Evaluation and Research.Review of environmental assessment for Keppra oral solution. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/021505_s000_Keppra_EAFONSI.pdf. Accessed January 27 2017."},{"key":"e_1_2_8_10_1","unstructured":"Center for Drug Evaluation and Research.Environmental assessment and finding of no significant impact for topamax (topiramate) tablets. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/96\/020505_000_environmental_rvw.pdf. Accessed January 27 2017."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(92)90070-A"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.07.007"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.54804.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.14301.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.12502.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70323-X"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.13733","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.13733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T16:56:57Z","timestamp":1694278617000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.13733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,7]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/epi.13733"],"URL":"https:\/\/doi.org\/10.1111\/epi.13733","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,7]]}}}